drugset
drugset / Trial / NCT07265843

Fibrinogen in Liver Transplant

NCT07265843 ↗

Phase 4 Not yet recruiting 60 enrolled Trauma Hemostatis and Oxygenation Research (THOR) Network
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.

Timeline

Start
2026-01-01
Primary completion
2028-03-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cryoprecipitate Antihemophilic Factor Protein / enzyme biologic — —
Comparator INTERCEPT Fibrinogen Complex Protein / enzyme biologic — —

Indications

No indication recorded.